Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community
Camilla Dalby Hansen, Johanne Kragh Hansen, Mads Israelsen, Peter Andersen, Laura Maarit Pikkupeura, Katrine Prier Lindvig, Sara Stinson, Helle Lindholm Schnefeld, Julie Tellerup, Maria Fogt, Nikolaj Torp, Maria Kjærgaard, K. Bech, Katrine Holtz Thorhauge, Stine Johansen, Ida Ziegler Spedtsberg, Emil Deluran, Ida Falk Villesen, Sönke Detlefsen, Torben Hansen, Aleksander Krag, Maja Thiele
Abstract
BACKGROUND & AIMS: Individuals with steatotic liver disease (SLD) are affected by metabolic dysfunction and/or high alcohol consumption; however, the prevalence of SLD in at-risk individuals remains underexplored. We aimed to investigate the prevalence and severity of SLD and its subclasses: metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic- and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD) in at-risk individuals. METHODS: and/or type 2 diabetes without prolonged increased alcohol consumption; or b) the alcohol cohort, comprising individuals with ongoing/prior increased alcohol consumption. We assessed liver steatosis by controlled attenuation parameter (CAP), liver fibrosis by liver stiffness measurements (LSM) and performed liver biopsies in participants with LSM ≥8 kPa. RESULTS: We included 3,123 participants; 1,599 in the metabolic cohort and 1,524 in the alcohol cohort. In total, 2,197 (70%) were diagnosed with SLD: 1,603 (51%) with MASLD, 398 (13%) with MetALD, and 196 (6.3%) with ALD. Of 307 (9.8%) with LSM ≥8 kPa, 169 underwent liver biopsy (55%). In the metabolic cohort, 1,237 (77%) had SLD, 147 (9.2%) had LSM ≥8 kPa, and 24 (1.5%) had biopsy-confirmed advanced liver fibrosis. In the alcohol cohort, 960 (63%) had SLD, 160 (10.5%) had LSM ≥8 kPa, and 46 (3.1%) had biopsy-confirmed advanced liver fibrosis. Across subclasses, ALD demonstrated the highest liver disease severity (LSM ≥8 kPa: 25%; biopsy-confirmed advanced fibrosis: 8%), and severity was comparable between MASLD and MetALD (LSM ≥8 kPa: 12%, biopsy-confirmed advanced fibrosis: 3%). CONCLUSIONS: Among individuals with cardiometabolic and/or alcohol risk factors, 70% had SLD, 10% had elevated liver stiffness, and 2% had biopsy-confirmed advanced liver fibrosis. IMPACT AND IMPLICATIONS: Steatotic liver disease (SLD) remains underdiagnosed in the general population. This study provides new population-based data on its prevalence and severity among individuals with metabolic and/or alcohol-related risk. These findings are relevant to clinicians, researchers, and public health planners, as prevalence data are essential to inform evolving screening strategies. Methodological limitations, including the cross-sectional design and limited generalizability, should be considered when interpreting the results. CLINICALTRIALS: GOV: NCT03308916.